Development of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis.
No Thumbnail Available
Identifiers
Date
2020-08-06
Authors
García-Argüello, Segundo Francisco
Lopez-Lorenzo, Beatriz
Cornelissen, Bart
Smith, Graham
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Insufficient apoptosis is a recognised hallmark of cancer. A strategy to quantitatively measure apoptosis in vivo would be of immense value in both drug discovery and routine patient management. The first irreversible step in the apoptosis cascade is activation of the "executioner" caspase-3 enzyme to commence cleavage of key structural proteins. One strategy to measure caspase-3 activity is Positron Emission Tomography using isatin-5-sulfonamide radiotracers. One such radiotracer is [18F]ICMT-11, which has progressed to clinical application. This review summarises the design and development process for [18F]ICMT-11, suggesting potential avenues for further innovation.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Michael acceptor, [18F]ICMT-11, apoptosis, caspase-3, positron emission tomography, pyrimidoindolone